(Teleborsa) – Novo Nordiska Danish giant active in the healthcare field and the largest European company by market capitalisation, collapses on the stock market after his medication CagriSema helped patients to achieve weight loss 22.7% higher than semaglutide in a late-stage trial, below the expected 25%..
“We are encouraged by CagriSema’s weight loss profile demonstrating superiority over both semaglutide and cagrilintide monotherapy in the REDEFINE 1 trial. This was achieved despite only 57% of patients achieving the highest dose of CagriSema,” he said Martin Holst LangeExecutive Vice President for Development at Novo Nordisk – With the information gained from the REDEFINE 1 trial, we intend to further explore the additional weight loss potential of CagriSema.”
Results from the second pivotal Phase 3 study, REDEFINE 2, in adults with type 2 diabetes and obesity or overweight are awaited for first half of 2025.
CagriSema subcutaneously once a week is being studied by Novo Nordisk as treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss reducing hunger, increasing the feeling of satiety and thus helping people to eat less and reduce their calorie intake.
Related News :